Pregnancy Is a Cardiovascular Stress Test

Cardiologists order stress tests to see how a heart performs under load, because demand reveals what rest conceals. Pregnancy is a stress test no one schedules and every pregnant woman takes. It places sustained, months-long cardiovascular demand on the heart and vasculature, and how the system responds is information that should be read as carefully as any result that comes off a treadmill.

The Mechanism

Pregnancy imposes extraordinary physiological demand on the cardiovascular system, and it does so rapidly. By the end of the first trimester, blood volume has already begun expanding, reaching 40 to 50 percent above baseline by the third trimester. Cardiac output, the volume of blood the heart pumps per minute, increases by 30 to 50 percent, driven by both increased stroke volume and modest increases in heart rate. The heart physically enlarges, left ventricular mass increases by roughly 30 percent in a normal pregnancy, and the vasculature must accommodate the higher flow while simultaneously maintaining the low-resistance placental circulation.

This is not a brief spike. A healthy pregnancy sustains this elevated cardiovascular state for the better part of nine months. In labor and delivery, demands intensify further: each uterine contraction can increase cardiac output by an additional 10 to 25 percent, and the weeks immediately after delivery involve rapid fluid shifts as the uteroplacental circulation closes and blood is redistributed back into the maternal system.

In a cardiovascular system with adequate reserve, these adaptations proceed without incident. The heart and vessels dilate appropriately, the kidneys regulate volume efficiently, and blood pressure remains controlled. When the system has underlying vulnerabilities, whether in blood pressure regulation, endothelial function, glucose metabolism, or cardiac reserve, the demand of pregnancy can expose them. This is the stress-test logic: the challenge is standardized, and the response is revealing.

Preeclampsia is not simply high blood pressure during pregnancy. It reflects failure of normal placental vascular development, impaired endothelial function, and dysregulated inflammatory and angiogenic signaling that affects the maternal vasculature systemically. Placental ischemia drives the release of excess soluble fms-like tyrosine kinase 1 (sFlt-1), which binds and neutralizes placental growth factor (PlGF) and vascular endothelial growth factor, disrupting normal vessel maintenance and endothelial repair. Women who develop preeclampsia have pre-existing endothelial and vascular susceptibilities that the pregnancy stress test surfaces. After delivery, those susceptibilities do not disappear; the blood pressure normalizes, but the underlying vascular biology remains and continues to accumulate risk over the following decades.

Gestational diabetes fits the same stress-test model, but in the metabolic domain rather than the vascular one. A normal pregnancy increases insulin demand by two to three times, because the placenta secretes hormones, particularly human placental lactogen and progesterone, that progressively reduce insulin sensitivity in maternal tissue. The pancreatic beta cells of a metabolically healthy woman compensate by increasing insulin secretion proportionally, and blood sugar remains controlled. Gestational diabetes develops when that compensation fails: a combination of pre-existing insulin resistance and insufficient beta-cell secretory capacity means the pancreas cannot meet the elevated demand pregnancy imposes. Kim et al., in a 2002 systematic review in Diabetes Care covering 28 cohort studies, found that women with a history of gestational diabetes have a seven-fold increased lifetime risk of developing type 2 diabetes compared to women with uncomplicated pregnancies. The gestational diabetes did not cause the metabolic vulnerability; it exposed a vulnerability that was already present, and it marked a woman whose beta-cell reserve is likely to erode further with age, weight gain, and subsequent metabolic stress. Even women with gestational diabetes who normalize blood sugar postpartum show residual deficits in first-phase insulin secretion on formal glucose tolerance testing years later.

Spontaneous preterm birth, particularly before 34 weeks without an identifiable cervical or anatomical cause, signals incomplete vascular remodeling in the placental bed. Normal placentation requires maternal spiral arteries to remodel from narrow, high-resistance vessels into wide, low-resistance conduits that flood the placenta with blood. When that remodeling is incomplete, placental perfusion is insufficient, and the uterus may trigger early labor. The same endothelial and thrombotic tendencies that impair spiral artery remodeling continue operating in the maternal systemic vasculature after delivery. Decidual vasculopathy and subclinical placental thrombosis are recognized contributors to preterm labor, and these pathways share biological substrate with the arterial disease that drives coronary and cerebrovascular risk in later life.

Peripartum cardiomyopathy is a distinct and less common pregnancy cardiac complication, but it illustrates the stress-test principle most starkly. It is defined as new-onset heart failure with reduced ejection fraction developing in the final month of pregnancy or within five months of delivery, in the absence of another identifiable cause. The incidence is estimated at roughly 1 in 1,000 to 1 in 4,000 deliveries in high-income countries, with substantially higher rates in populations with multiple gestations and advanced maternal age. Hilfiker-Kleiner and colleagues, writing in Nature Reviews Cardiology in 2014, proposed that peripartum cardiomyopathy involves cleavage of prolactin into an antiangiogenic 16 kDa fragment that is cardiotoxic, coupled with oxidative stress and impaired cardiac vascular supply at the time of highest metabolic demand. Most women recover full cardiac function within six to twelve months, but approximately 20 percent are left with persistent left ventricular dysfunction and are at elevated risk of heart failure with subsequent pregnancies and throughout adult life.

What the Evidence Shows

The evidence linking pregnancy complications to long-term cardiovascular risk has matured substantially in the past fifteen years.

The HUNT study in Norway, one of the largest population cohorts examining this relationship, followed more than 17,000 women over more than two decades. Researchers Romundstad, Davey Smith, Nilsen, and Vatten reported in 2010 in Circulation that women who had preeclampsia had a two-fold increase in cardiovascular mortality compared to women with uncomplicated pregnancies, an effect that persisted after adjustment for shared risk factors like obesity and diabetes. The association was stronger for early-onset preeclampsia, consistent with the idea that more severe placental dysfunction signals more significant underlying vascular disease.

The Nurses’ Health Study II specifically examined gestational diabetes and subsequent risk. Rich-Edwards and colleagues, reporting in BMJ in 1999 and with longer follow-up in subsequent analyses, found that women who had gestational diabetes had substantially elevated rates of type 2 diabetes in the years following pregnancy, and that the transition carried forward into elevated cardiovascular risk. Women with gestational diabetes who do not develop type 2 diabetes still show evidence of beta-cell dysfunction and impaired insulin sensitivity on formal testing years after the pregnancy.

The ARIC (Atherosclerosis Risk in Communities) study contributed data on preterm birth. Catov et al., in an analysis published in Journal of the American Heart Association, found that women with a history of spontaneous preterm birth had higher rates of coronary artery disease, heart failure, and cardiovascular mortality over follow-up, with risk elevations beginning in the first decade after delivery and persisting. A history of delivering before 37 weeks, particularly before 32 weeks, is now recognized in American College of Cardiology guidelines as a risk-enhancing factor to count in cardiovascular risk assessment.

The CARPREG (Cardiac Disease in Pregnancy) and subsequent CARPREG II work by Silversides, Grewal, and colleagues, published in the Journal of the American College of Cardiology in 2018, developed and validated risk prediction for women with existing cardiac disease through pregnancy, but the underlying principle generalizes: pregnancy is a structured physiological challenge that produces interpretable cardiovascular information.

Magnussen et al., reporting in Arteriosclerosis, Thrombosis, and Vascular Biology in 2011, examined cardiovascular risk factor clustering in Norwegian women with prior preeclampsia at ten-year intervals after delivery. They found that women with prior preeclampsia had significantly higher levels of blood pressure, triglycerides, fasting glucose, and body mass index compared to women with uncomplicated pregnancies, and that these differences widened rather than narrowed over the decade of follow-up. The implication is that a prior preeclamptic pregnancy does not simply confer a static risk increment; it marks a woman whose cardiometabolic trajectory diverges more steeply from her peers with each passing year.

A 2019 meta-analysis by Bellamy et al. in Lancet summarized risk across complications: preeclampsia was associated with a four-fold increase in hypertension, a two-fold increase in ischemic heart disease, and a two-fold increase in stroke over an average follow-up of more than fourteen years. The relative risks are large and consistent.

What to Do This Week

1. Write down your complete pregnancy history, including the number of pregnancies, the gestational age at delivery for each, any complications such as preeclampsia, gestational hypertension, gestational diabetes, preterm delivery, fetal growth restriction, or placental abruption, and how severe and how early those complications were. Note whether any complications required hospitalization or early delivery. This is cardiovascular information, not just obstetric history, and it belongs in your permanent health record.

2. Bring that written history to your next primary care or cardiology appointment and specifically ask: “Should my pregnancy complications affect when you start screening me for cardiovascular risk, and do they change my blood pressure or lipid targets?” Standard intake forms frequently do not ask about obstetric history, so the information will not be volunteered without prompting. Hand the written summary to your provider rather than relying on a verbal history taken under time pressure.

3. If you had preeclampsia, gestational diabetes, or spontaneous preterm birth, ask whether you should be starting blood pressure monitoring, lipid screening, or glucose monitoring earlier than age-based guidelines alone would suggest. The ACC/AHA 2019 cardiovascular risk guidelines explicitly list these complications as risk-enhancing factors that can shift treatment thresholds downward. Specifically, ask whether a fasting lipid panel, fasting glucose, and blood pressure measurement should be done now, and at what interval they should be repeated.

4. If you are currently pregnant and developing hypertension or elevated blood sugars, understand that the cardiovascular relevance of these findings does not end at delivery. Arrange follow-up at six to twelve weeks postpartum with your primary care provider, separate from the obstetric postpartum visit, and explicitly ask about long-term cardiovascular monitoring. If your blood pressure has not fully normalized by twelve weeks postpartum, that is clinically significant and warrants formal evaluation rather than a watch-and-wait approach.

5. If you had an uncomplicated pregnancy, recognize it as a reassuring data point and not a permanent clearance. Continue standard cardiovascular care, because risk accrues with age and other factors regardless of obstetric history, and the menopause transition adds a significant new variable for vascular risk in women. An uncomplicated pregnancy at 28 does not cancel the cardiovascular work of staying monitored at 48 and 58.

Who Needs Closer Monitoring

Not every woman with a pregnancy history needs the same surveillance intensity. Three tiers describe the current clinical thinking, informed by the 2019 ACC/AHA cholesterol guidelines and the 2022 American Heart Association scientific statement on pregnancy complications and cardiovascular risk authored by Parikh et al.

Women with uncomplicated pregnancies belong in the standard screening tier: routine cardiovascular risk assessment beginning around age 40 to 45, blood pressure measured at every clinical encounter, and lipid screening at intervals appropriate to their individual risk factors. A smooth pregnancy is a favorable data point and should be counted as one. It does not, however, substitute for the age-related assessments that apply to all women.

Women with a single pregnancy complication, such as gestational diabetes, gestational hypertension, spontaneous preterm birth, or fetal growth restriction, should begin cardiovascular risk screening five to ten years earlier than age-based guidelines alone would recommend. A woman who had gestational diabetes at 30 should have formal lipid, glucose, and blood pressure assessment well before 40, not at the standard midlife entry point. The ACC/AHA explicitly designates these conditions as risk enhancers: when a woman is on the borderline of treatment decisions, a history of one of these complications should tip the decision toward closer monitoring or earlier intervention.

Women with severe or early-onset preeclampsia (before 34 weeks), two or more pregnancy complications of any type, or peripartum cardiomyopathy should be treated as carrying elevated cardiovascular risk starting immediately after the affected pregnancy, regardless of age. A 32-year-old with early-onset preeclampsia is not in a low-risk tier by virtue of being 32. She warrants a fasting lipid panel and blood pressure target in the range appropriate for higher-risk patients now, coronary artery calcium scoring considered as a baseline in her late thirties, and intensified follow-up through the menopause transition. The number of years since the complication matters less than the biology the complication revealed.

The practical gap in this framework is that no clinical system reliably captures obstetric history and routes it into cardiovascular care. Until that gap closes, the responsibility falls to the woman herself to carry her pregnancy history forward, treat it as cardiovascular data, and ensure it is read by the clinicians managing her health for the next four decades.

Pregnancy is a cardiovascular stress test that every mother takes, and the result, whether a smooth response or a complication, is information that belongs in her cardiovascular record for the rest of her life. Reading that result, years after the delivery that produced it, is how the most diagnostic data many women ever generate finally reaches the care it should be informing.